Role of anti-β-glucan antibody in host defense against fungi

FEMS immunology and medical microbiology Pub Date : 2005-04-01 DOI:10.1016/j.femsim.2004.12.012

Ken-ichi Ishibashi , Masaharu Yoshida , Iwao Nakabayashi , Hiroyasu Shinohara , Noriko N. Miura , Yoshiyuki Adachi , Naohito Ohno

{"title":"Role of anti-β-glucan antibody in host defense against fungi","authors":"Ken-ichi Ishibashi , Masaharu Yoshida , Iwao Nakabayashi , Hiroyasu Shinohara , Noriko N. Miura , Yoshiyuki Adachi , Naohito Ohno","doi":"10.1016/j.femsim.2004.12.012","DOIUrl":null,"url":null,"abstract":"<div>We have recently detected an anti-β-glucan antibody in normal human and normal mouse sera. The anti-β-glucan antibody showed reactivity to pathogenic fungal Aspergillus and Candida cell wall glucan. Anti-β-glucan antibody could bind whole Candida cells. It also enhanced the candidacidal activity of macrophages in vitro. The anti-β-glucan antibody titer of DBA/2 mice intravenously administered either Candida or Aspergillus solubilized cell wall β-glucan decreased remarkably dependent on dose. Moreover, in deep mycosis patients, the anti-β-glucan antibody titer decreased, and this change correlated with clinical symptoms and other parameters such as C-reactive protein. It was suggested that the anti-β-glucan antibody formed an antigen–antibody complex and participated in the immune response as a molecule recognizing pathogenic fungi.</div>","PeriodicalId":12220,"journal":{"name":"FEMS immunology and medical microbiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2005-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.femsim.2004.12.012","citationCount":"46","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FEMS immunology and medical microbiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928824405000052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 46

Abstract

We have recently detected an anti-β-glucan antibody in normal human and normal mouse sera. The anti-β-glucan antibody showed reactivity to pathogenic fungal Aspergillus and Candida cell wall glucan. Anti-β-glucan antibody could bind whole Candida cells. It also enhanced the candidacidal activity of macrophages in vitro. The anti-β-glucan antibody titer of DBA/2 mice intravenously administered either Candida or Aspergillus solubilized cell wall β-glucan decreased remarkably dependent on dose. Moreover, in deep mycosis patients, the anti-β-glucan antibody titer decreased, and this change correlated with clinical symptoms and other parameters such as C-reactive protein. It was suggested that the anti-β-glucan antibody formed an antigen–antibody complex and participated in the immune response as a molecule recognizing pathogenic fungi.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗β-葡聚糖抗体在宿主抗真菌中的作用

我们最近在正常人和正常小鼠血清中检测到一种抗β-葡聚糖抗体。抗β-葡聚糖抗体对致病性真菌曲霉和念珠菌细胞壁葡聚糖具有反应性。抗β-葡聚糖抗体能结合整个念珠菌细胞。体外培养的巨噬细胞也能增强其杀灭念珠菌活性。静脉给药念珠菌或曲霉菌溶解细胞壁β-葡聚糖的DBA/2小鼠抗β-葡聚糖抗体滴度随剂量显著降低。此外，在深部真菌病患者中，抗β-葡聚糖抗体滴度下降，这种变化与临床症状和c反应蛋白等参数相关。提示抗β-葡聚糖抗体形成抗原-抗体复合物，作为识别病原真菌的分子参与免疫应答。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

FEMS immunology and medical microbiology 医学-传染病学

自引率

0.00%

发文量

审稿时长

3-8 weeks